Behind the Mystery: NRG1 Fusions
May 31, 2021
Only between five and ten percent of pancreatic cancer patients survive five years after diagnosis. To increase those odds, doctors are focusing more on genetic abnormalities that cause this deadly cancer. One of them is NRG1 fusions, rare oncogenic drivers in different solid tumors like cancer of the pancreas, lung, colon, prostate, and breast.
In patients that have NRG1 fusions, too much of the growth factor NRG1 (sometimes called heregulin) may be produced, which is capable of causing cancer cells to grow and divide in an uncontrolled manner. Blocking NRG1 and its cancer-driving activity with medicine may help fight a patient’s cancer.
We’ll hear more from Dr. Manuel Hidalgo and a patient who was diagnosed with NRG1 fusion pancreatic cancer.
PROMOTED
Celebrate Mother’s Day with The Balancing Act’s exclusive guide, dedicated to creating a day just as special as the moms in our lives. Dive into a treasure trove of activities, delectable recipes, and thoughtful gift ideas curated to make this Mother’s Day an unforgettable celebration of love and appreciation.
PROMOTED
Today's show includes advanced oral care, poverty educational resources, delicious Thai food, funeral planning, and so much more
PROMOTED
Parikh Law Group was founded in 2010 to provide solid, experienced, and affordable representation.
Comments